Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Prostate-specific symptoms of prostate cancer in a German general population

Abstract

Predominant symptoms in prostate cancer patients are erectile dysfunctions and urinary problems. As decreases of these functions can be attributed to disease and treatment but also to age-related decreases, we conducted a study on a German reference population measuring general quality of life (QoL) as well as prostate-specific symptoms. In cooperation with a German health insurance company, 3000 questionnaires were mailed to a randomly selected sample of men aged 45–75 years. Questionnaires used were the EORTC QLQ-C30 and a prostate-specific module (PSM). One thousand one hundred and fifty questionnaires were returned (response rate: 37.6%). QoL data from this reference population were compared to QoL data from a historical cohort study of prostate cancer patients following either prostatectomy or radiotherapy. In terms of general QoL, the reference population showed similar QoL scores as prostatectomy patients, but better scores than radiotherapy patients. On the PSM, the reference sample showed better overall QoL, but a surprisingly high extent of erectile dysfunction, urinary problems and psychic strain. Taking into account the sensitive topic of this study (sexuality and urinary problems), the response rate is more than satisfying. Older men in our randomly selected, population-based sample do not show perfect erectile and urinary function. These findings should be considered when interpreting QoL data of prostate cancer patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Zusammenarbeit mit dem Robert-Koch-Institut (Hrg.): Krebs in Deutschland- Häufigkeiten und Trends. 4. überarbeitete, aktualisierte Ausgabe, Saarbrücken, 2004.

  2. Middleton RG, Thompson IM, Austenfeld MS, Cooner WH, Correa RJ, Gibbons RP et al. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol 1995; 154: 2144–2148.

    Article  CAS  Google Scholar 

  3. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the prostate cancer outcomes study. J Natl Cancer Inst 2000; 92: 1582–1592.

    Article  CAS  Google Scholar 

  4. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–376.

    Article  CAS  Google Scholar 

  5. Fayers P, Aaronson N, Bjordal K, Curran D, Groenvold M, on behalf of the EORTC Quality of Life Study Group. Guidelines for Developing Questionnaire Modules. Quality of Life Study Group: Brussels, 1999.

  6. Bestmann B, Rohde V, Siebmann JU, Galalae R, Weidner W, Küchler T . Validation of the German prostate specific module (PSM). World J Urol 2006; 19: 1–7.

    Google Scholar 

  7. Schwarz R, Hinz A . Reference data for the quality of life questionnaire EORTC-QLQ-C-30 in general German population. Eur J Cancer 2001; 37: 1345–1351.

    Article  CAS  Google Scholar 

  8. D'Amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, Schultz D et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001; 166: 2185–2188.

    Article  CAS  Google Scholar 

  9. Osoba D, Rodrigues G, Myles J, Zee B, Pater J . Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139–144.

    Article  CAS  Google Scholar 

  10. Litwin MS . Health related quality of life in older men without prostate cancer. J Urol 1999; 161: 1180–1184.

    Article  CAS  Google Scholar 

  11. Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S . Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ=C30 (+3). J Clin Oncol 1998; 16: 1188–1196.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from Takeda Pharma Inc. (Japan) and Sancura BKK (Germany).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to B Bestmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bestmann, B., Loetters, C., Diemer, T. et al. Prostate-specific symptoms of prostate cancer in a German general population. Prostate Cancer Prostatic Dis 10, 52–59 (2007). https://doi.org/10.1038/sj.pcan.4500921

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500921

Keywords

This article is cited by

Search

Quick links